CVM Rules in Favor of Goldman Sachs and Centaurus on Oncoclínicas

The technical area of Brazil’s Securities and Exchange Commission (CVM) has ruled in favor of Goldman Sachs and Centaurus Capital, deciding that Centaurus's recent share acquisition did not trigger a mandatory tender offer (OPA) for Oncoclínicas (ONCO3). The Superintendency of Securities Registration (SRE) accepted the defense that Centaurus already held an indirect stake of over 15% in the healthcare company prior to its 2021 initial public offering (IPO). This position was maintained through a co-investment vehicle controlled by Goldman Sachs, exempting the transaction from the "poison pill" clause in the corporate bylaws.

For investors, this regulatory decision eliminates the immediate risk of a costly, multi-billion-real mandatory tender offer. The resolution provides significant relief to the capital structure of Oncoclínicas and stabilizes the stock, which has faced volatility amid the corporate dispute. The technical area concluded that the share movements represented a redistribution of an existing position between Goldman Sachs and Centaurus rather than the entry of a new, major shareholder.

However, the legal battle is not entirely over. Minority shareholder Latache Capital, which holds a 14.59% stake in Oncoclínicas, announced it will appeal the decision to the CVM’s collegiate board, maintaining its thesis that a mandatory OPA is required. The dispute unfolds during a broader negative session for Brazilian equities, with the Ibovespa index down 0.68% to 172,024.12 points. Among major blue chips, PETR4 fell 0.89% to 37.8, VALE3 slipped 0.32% to 77.88, and ITUB4 declined 0.54% to 42.18.